MSB is developing Ryoncil - an IV stem cell therapy for the treatment of acute graft versus host disease (aGVHD) in paediatrics. aGCHD is a potentially life threatening (up to 70-90% mortality) complication of bone marrow transplants (indicated for leukemia/lymphoma etc). Ryoncil has been accepted by the FDA for priority review with a PDUFA action date of US 30th...
Hello Fellow Traders!
The XJO (ASX200) has sold off from the peak made on August 25th following the SPX(US500) and Nasdaq during uncertain global times and Covid numbers starting to increase again in Europe. While the XJO continued to fall in the past 5 trading days, MSB has experienced supreme buying pressure continuing to retest $5.00.
MSB is a Bio –...